Claims
- 1. A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and (b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.
- 2. A method of claim 1 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate or a pharmaceutically acceptable salt of said GABA agonist.
- 3. A method of claim 2 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin or a pharmaceutically acceptable salt of said GABA agonist.
- 4. A method of claim 3 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt thereof.
- 5. A method of claim 3 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt thereof.
- 6. A method of claim 1 wherein said aldose reductase inhibitor is fidarestat, epalrestat, minalrestat, SPR-210, zenarestat, zopolrestat or a pharmaceutically acceptable salt of said aldose reductase inhibitor.
- 7. A method of claim 1 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.
- 8. A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment a pharmaceutical composition comprising(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and (b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI.
- 9. A method of claim 8 wherein said pharmaceutical composition additionally comprises a pharmaceutically acceptable vehicle, carrier or diluent.
- 10. A method of claim 8 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.
- 11. A pharmaceutical composition comprising:a. an amount of a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and b. an amount of an ARI or a pharmaceutically acceptable salt of said ARI.
- 12. A pharmaceutical composition of claim 11 additionally comprising a pharmaceutically acceptable vehicle, carrier or diluent.
- 13. A pharmaceutical composition of claim 12 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, or a pharmaceutically acceptable salt of said GABA agonist.
- 14. A pharmaceutical composition of claim 13 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, or a pharmaceutically acceptable salt of said GABA agonist.
- 15. A pharmaceutical composition of claim 14 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt of said pregabalin.
- 16. A pharmaceutical composition of claim 14 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt of said gabapentin.
- 17. A pharmaceutical composition of claim 12 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarestat, zopoir stat, or a pharmaceutically acceptable salt of said ARI.
- 18. A pharmaceutical composition of claim 17 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, or a pharmaceutically acceptable salt of said GABA agonist.
- 19. A pharmaceutical composition of claim 18 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate and pregabalin, or a pharmaceutically acceptable salt of said GABA agonist.
- 20. A pharmaceutical composition of claim 19 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt of said pregabalin.
- 21. A pharmaceutical composition of claim 19 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt of said gabapentin.
- 22. A kit for achieving a therapeutic effect in a mammal comprising:a. an amount of a GABA agonist, or a pharmaceutically acceptable salt of said GABA agonist, and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form; b. an amount of an ARI, or a pharmaceutically acceptable salt of said ARI, and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form; and c. a container.
- 23. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and (b) an amount of a second compound, said second compound being an ARI or a pharmaceutically acceptable salt of said ARI wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.
- 24. A method of claim 23 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, or a or a pharmaceutically acceptable salt of said GABA agonist.
- 25. A method of claim 24 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, pharmaceutically acceptable salt of said GABA agonist.
- 26. A method of claim 25 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt of said pregabalin.
- 27. A method of claim 25 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt of said gabapentin.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a U.S. non-provisional application. This application claims the benefit of U.S. No. 60/250,448 filed on Nov. 30, 2000, under 35 USC 119(e).
US Referenced Citations (37)
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 0045818 |
Aug 2000 |
WO |
WO 0050034 |
Aug 2000 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/250448 |
Nov 2000 |
US |